Hepatitis

Hepatitis A

• Update to payer value deck in Hepatitis A
• Payer material development for vaccines in hepatitis A
• e-v@luate platform on vaccines for hepatitis A
• Burden of disease literature review on hepatitis A in the UK and Ireland

Hepatitis B

• Systematic literature review of a treatment for chronic hepatitis B
• Preparation of a NICE submission for a hepatitis B drug
• SMC submission for a treatment for chronic hepatitis B
• Database analysis to calculate the economic burden of hepatitis B in the UK

Hepatitis C

• Therapeutic area strategy analysis and reporting in chronic hepatitis C virus
• Biomarkers in the treatment of hepatitis C virus infected patients – personalised medicine
• Maximizing the use of a treatment for hepatitis C-infected patients through personalised medicine – extending the tool to additional treatments
• Treatment algorithm for hepatitis C treatment
• One-pager value communication tool for Hepatitis C
• Comprehensive literature research in chronic hepatitis C in Asian countries
• Database development and analysis in hepatitis C
• Concept elicitation and cognitive debriefing interviews with hepatitis C patients in multiple countries
• Development of an EMA summary document for several instruments used in hepatitis C trials
• Development of a PRO outcomes summary document and communications support in hepatitis C trials
• Description, interpretation and analysis of pooled data related to the use of several questionnaires, scales and screening tests in three hepatitis C clinical trials
• Conceptual model for patients with hepatitis C
• Psychometric validation of a hepatitis C symptom checklist using phase III trial data
• Treatment patterns, healthcare utilization and costs associated with the hepatitis C virus in Japan
• Selection of PRO measures for hepatitis C trials